Post-Herpetic Neuralgia
5
Pipeline Programs
3
Companies
2
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
4
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Viatrispregabalin
SandozEMA401
Clinical Trials (2)
Total enrollment: 385 patients across 2 trials
Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia
Start: Oct 2004Est. completion: Jun 2006255 patients
Phase 4Completed
Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)
Start: Jun 2017Est. completion: Mar 2019130 patients
Phase 2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.